Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Agios Pharmaceuticals's operating assets for the quarter that ended in Mar. 2026 was €926.75 Mil. Agios Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2026 was €34.71 Mil. Agios Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was €1,107.83 Mil. Therefore, Agios Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.81.
Agios Pharmaceuticals Scaled Net Operating Assets Related Terms
Agios Pharmaceuticals Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Agios Pharmaceuticals's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals Scaled Net Operating Assets Chart
FRA:8AP vs CAPR, SNDX, SLS: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Agios Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.81 mean?
Agios Pharmaceuticals (FRA:8AP) has a Scaled Net Operating Assets of 0.81 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Scaled Net Operating Assets too high?
Agios Pharmaceuticals' current Scaled Net Operating Assets is 0.81. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Scaled Net Operating Assets compare to CAPR and SNDX?
Agios Pharmaceuticals' Scaled Net Operating Assets of 0.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Scaled Net Operating Assets is 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (FRA:8AP) is currently considered Possible Value Trap. The stock's GF Value™ is €67.84, compared to a current price of €31.00 — trading 54.3% below its estimated fair value. The current Scaled Net Operating Assets is 0.81. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Scaled Net Operating Assets is 0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of €31.00 is trading 54.3% below its estimated GF Value™ of €67.84.
GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:8AP:
Scaled Net Operating Assets: 0.81
GF Value™: €67.84 vs. price of €31.00 (54.3% below fair value)
No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score
Get the complete analysis for FRA:8AP
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8AP has been successfully added to your 
